{"protocolSection":{"identificationModule":{"nctId":"NCT00751777","orgStudyIdInfo":{"id":"ELT207"},"organization":{"fullName":"Intercell USA, Inc.","class":"INDUSTRY"},"briefTitle":"Traveler's Diarrhea (TD) Automated Process","officialTitle":"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of a Two Vaccination Regimen With an LT Vaccine Patch in Healthy Adults"},"statusModule":{"statusVerifiedDate":"2020-01","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2008-09"},"primaryCompletionDateStruct":{"date":"2009-11","type":"ACTUAL"},"completionDateStruct":{"date":"2009-11","type":"ACTUAL"},"studyFirstSubmitDate":"2008-09-11","studyFirstSubmitQcDate":"2008-09-11","studyFirstPostDateStruct":{"date":"2008-09-12","type":"ESTIMATED"},"resultsFirstSubmitDate":"2014-01-30","resultsFirstSubmitQcDate":"2014-03-17","resultsFirstPostDateStruct":{"date":"2014-04-21","type":"ESTIMATED"},"lastUpdateSubmitDate":"2020-01-16","lastUpdatePostDateStruct":{"date":"2020-01-29","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Intercell USA, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false},"descriptionModule":{"briefSummary":"To evaluate and compare the immune responses and safety following a two vaccination regimen by transcutaneous immunization with heat-labile enterotoxin of E. coli (LT) patches or placebo patches."},"conditionsModule":{"conditions":["Prevention of Travelers' Diarrhea"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":120,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Group 1: 37.5 µg LT patch","type":"EXPERIMENTAL","description":"80 subjects will receive a two vaccination regimen with a LT patch.","interventionNames":["Biological: heat-labile enterotoxin of E. coli (LT)"]},{"label":"Group 2: 0 µg LT patch (placebo)","type":"PLACEBO_COMPARATOR","description":"40 subjects will receive a two vaccination regimen with a placebo patch.","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"heat-labile enterotoxin of E. coli (LT)","description":"Travelers' Diarrhea Vaccine System","armGroupLabels":["Group 1: 37.5 µg LT patch"],"otherNames":["TD Vaccine System"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Travelers' Diarrhea Vaccine System","armGroupLabels":["Group 2: 0 µg LT patch (placebo)"],"otherNames":["TD Vaccine System"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Geometric Mean Titer (GMT) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo","timeFrame":"Day 0, Day 14, Day 21, Day 28, Day 35, Day 90, Day 194"},{"measure":"Geometric Mean Fold Ratio (GMFR) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo","description":"GMFRs relative to the baseline titer were determined at each post-baseline time point. All GMFRs were based on log10-transformed data.","timeFrame":"Day 14, Day 21, Day 28, Day 35, Day 90, Day 194"},{"measure":"Seroconversion (SCR) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo","description":"Definition of SCR:\n\n* Seroconversion IgG: ≥ 2-fold rise of LT IgG titer relative to baseline\n* Seroconversion IgA: ≥ 4-fold rise of LT IgA titer relative to baseline","timeFrame":"Day 14, Day 21, Day 28, Day 35, Day 90, Day 194"}],"secondaryOutcomes":[{"measure":"Evaluation of Safety of LT Vaccine Patch After First and Second Vaccination Compared to Placebo Patch","description":"LT subjects (Group 1) were followed for six months longer (until Day 380) than Placebo subjects (Group 2) (until Day 194)","timeFrame":"13 months"},{"measure":"Evaluation of Residual LT in the Patch and on the Skin at the Patch Site Post-wear","timeFrame":"1 month"},{"measure":"Evaluation of LT-specific Immune Responses One-year After Original Treatment Regimen in LT Patch Group","description":"GMT","timeFrame":"13 months"},{"measure":"Evaluation of LT-specific Immune Responses One Year After Original Treatment Regimen in LT Patch Group","description":"GMFR","timeFrame":"13 months"},{"measure":"Evaluation of LT-specific Immune Responses One Year After Original Treatment Regimen in LT Patch Group","description":"SCR","timeFrame":"13 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy adult males or females, 18-64 years of age (inclusive) at the planned start of the study (first vaccination on Day 0)\n* Signed Informed Consent\n* Women who are not post-menopausal or surgically sterile must have a negative serum/urine pregnancy test at screening and within 24 hours of each vaccination with understanding (through Informed Consent process) to not become pregnant and to employ an effective form of birth control for the duration of the study. Acceptable forms of birth control are: abstinence, hormonal contraceptives (oral, injectable, implant, patch, ring), double-barrier contraceptives (condom or diaphragm, with spermicide), and IUD.\n\nExclusion Criteria:\n\n* Laboratory abnormalities \\[as determined by the Toxicity Grading Scale (grade 1 4)\\] at laboratory screening\n* Abnormalities at physical examination \\[as determined by the Toxicity Grading Scale (grade 1-4)\\]\n* Known allergies to any component of the vaccine\n* Known allergies to adhesives\n* Participated in research involving investigational product within 30 days before planned date of first vaccination or within 90 days after first vaccination\n* Donated blood or blood products such as plasma within 30 days prior to planned date of first vaccination or within 90 days after first vaccination\n* Ever received investigational enterotoxigenic E. coli, LT, or LT (R192G) or NasalFlu, Berna Biotech, Ltd\n* Ever received cholera toxin or vaccine (e.g. Orochol™, Dukoral™)\n* History of diarrhea while traveling in a developing country within the last year\n* History of abdominal surgery (excluding C-section, hysterectomy, cosmetic surgery, liposuction, appendectomy, cholecystectomy, ventral hernia repair, and other surgeries not pertaining to gastrointestinal problems) or history of, or recent acute gastrointestinal illness\n* Positive serology for HIV-1, HIV-2, HBsAg, or HCV\n* Medical history of acute or chronic skin disease at vaccination area(s)\n* Active skin allergy\n* Signs of acute skin infection, sunburn or skin abnormalities at the vaccination area(s) including fungal infections, severe acne, or active contact dermatitis, or a history of keloid formation\n* Excessively hirsute and unwilling to clip hair at the vaccination area(s)\n* Visible tattoos or marks (tattoos/scars) at the vaccination area(s) that would prevent appropriate dermatologic monitoring of the vaccination site(s)\n* Fever greater than or equal to 38.0°C (100.4°F) at the time of planned vaccination\n* Women who are pregnant or breastfeeding\n* Acute illness at screening and unresolved at time of planned vaccination\n* Employee of the investigational site","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Eric Sheldon, MD","affiliation":"Miami Research Associates","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Solano Clinical Research","city":"Vallejo","state":"California","zip":"94589","country":"United States","geoPoint":{"lat":38.10409,"lon":-122.25664}},{"facility":"Miami Research Associates","city":"South Miami","state":"Florida","zip":"33143","country":"United States","geoPoint":{"lat":25.7076,"lon":-80.29338}},{"facility":"Clinical Trials of Texas","city":"San Antonio","state":"Texas","zip":"78229","country":"United States","geoPoint":{"lat":29.42412,"lon":-98.49363}}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Group 1: 37.5 µg LT Patch","description":"heat-labile enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System"},{"id":"FG001","title":"Group 2: 0 µg LT Patch (Placebo)","description":"Placebo: Travelers' Diarrhea Vaccine System"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"81"},{"groupId":"FG001","numSubjects":"39"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","comment":"Day 380: study completion for LT group","numSubjects":"70"},{"groupId":"FG001","comment":"Day 194: study completion for placebo group","numSubjects":"36"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"11"},{"groupId":"FG001","numSubjects":"3"}]}]}]},"baselineCharacteristicsModule":{"populationDescription":"Intent-to-Treat (ITT) Population: all study subjects who were consented, randomized, and had a baseline serology","groups":[{"id":"BG000","title":"Group 1: 37.5 µg LT Patch","description":"heat-labile enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System"},{"id":"BG001","title":"Group 2: 0 µg LT Patch (Placebo)","description":"Placebo: Travelers' Diarrhea Vaccine System"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"81"},{"groupId":"BG001","value":"39"},{"groupId":"BG002","value":"120"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"34.1","spread":"10.2"},{"groupId":"BG001","value":"35.3","spread":"13.0"},{"groupId":"BG002","value":"34.5","spread":"11.2"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"46"},{"groupId":"BG001","value":"26"},{"groupId":"BG002","value":"72"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"48"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titer (GMT) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo","populationDescription":"Immunogenicity Evaluable Population (IEP): all study subjects who are consented, randomized, received the assigned treatments (both vaccinations), and had blood drawn for immunogenicity testing at baseline (Day 0) and both of the following time points: Day 21 and Day 35.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"geometric mean titer","timeFrame":"Day 0, Day 14, Day 21, Day 28, Day 35, Day 90, Day 194","groups":[{"id":"OG000","title":"Group 1: 37.5 µg LT Patch","description":"heat-labile enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System"},{"id":"OG001","title":"Group 2: 0 µg LT Patch (Placebo)","description":"Placebo: Travelers' Diarrhea Vaccine System"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"34"}]}],"classes":[{"title":"GMT LT IgG - Day 0","categories":[{"measurements":[{"groupId":"OG000","value":"432.6","lowerLimit":"349.0","upperLimit":"536.2"},{"groupId":"OG001","value":"400.5","lowerLimit":"290.5","upperLimit":"552.2"}]}]},{"title":"GMT LT IgG - Day 14","categories":[{"measurements":[{"groupId":"OG000","value":"4477.5","lowerLimit":"3249.6","upperLimit":"6169.4"},{"groupId":"OG001","value":"490.6","lowerLimit":"303.8","upperLimit":"792.2"}]}]},{"title":"GMT LT IgG - Day 21","categories":[{"measurements":[{"groupId":"OG000","value":"9107.7","lowerLimit":"6791.9","upperLimit":"12213.0"},{"groupId":"OG001","value":"462.1","lowerLimit":"298.0","upperLimit":"716.6"}]}]},{"title":"GMT LT IgG - Day 28","categories":[{"measurements":[{"groupId":"OG000","value":"13411.9","lowerLimit":"10420","upperLimit":"17263.5"},{"groupId":"OG001","value":"372.6","lowerLimit":"255.4","upperLimit":"543.4"}]}]},{"title":"GMT LT IgG - Day 35","categories":[{"measurements":[{"groupId":"OG000","value":"15024.3","lowerLimit":"11893","upperLimit":"18979.4"},{"groupId":"OG001","value":"383.6","lowerLimit":"270.5","upperLimit":"544.0"}]}]},{"title":"GMT LT IgG - Day 90","categories":[{"measurements":[{"groupId":"OG000","value":"6823.7","lowerLimit":"5553.1","upperLimit":"8385.1"},{"groupId":"OG001","value":"156.2","lowerLimit":"114.5","upperLimit":"213.1"}]}]},{"title":"GMT LT IgG - Day 194","categories":[{"measurements":[{"groupId":"OG000","value":"2489.2","lowerLimit":"1965.5","upperLimit":"3152.4"},{"groupId":"OG001","value":"100.2","lowerLimit":"70.7","upperLimit":"142.0"}]}]},{"title":"GMT LT IgA - Day 0","categories":[{"measurements":[{"groupId":"OG000","value":"49.4","lowerLimit":"37.4","upperLimit":"65.1"},{"groupId":"OG001","value":"58.9","lowerLimit":"38.9","upperLimit":"89.1"}]}]},{"title":"GMT LT IgA - Day 14","categories":[{"measurements":[{"groupId":"OG000","value":"395.6","lowerLimit":"289.9","upperLimit":"539.8"},{"groupId":"OG001","value":"59.1","lowerLimit":"37.2","upperLimit":"94.1"}]}]},{"title":"GMT LT IgA - Day 21","categories":[{"measurements":[{"groupId":"OG000","value":"619.2","lowerLimit":"466.2","upperLimit":"822.4"},{"groupId":"OG001","value":"60.9","lowerLimit":"39.8","upperLimit":"93.0"}]}]},{"title":"GMT LT IgA - Day 28","categories":[{"measurements":[{"groupId":"OG000","value":"780.0","lowerLimit":"603.8","upperLimit":"1007.7"},{"groupId":"OG001","value":"53.9","lowerLimit":"36.8","upperLimit":"79.1"}]}]},{"title":"GMT LT IgA - Day 35","categories":[{"measurements":[{"groupId":"OG000","value":"681.2","lowerLimit":"526.1","upperLimit":"882.0"},{"groupId":"OG001","value":"52.5","lowerLimit":"35.7","upperLimit":"77.3"}]}]},{"title":"GMT LT IgA - Day 90","categories":[{"measurements":[{"groupId":"OG000","value":"348.1","lowerLimit":"280.3","upperLimit":"432.4"},{"groupId":"OG001","value":"40.5","lowerLimit":"29.2","upperLimit":"56.1"}]}]},{"title":"GMT LT IgA - Day 194","categories":[{"measurements":[{"groupId":"OG000","value":"177.0","lowerLimit":"145.3","upperLimit":"215.5"},{"groupId":"OG001","value":"32.6","lowerLimit":"24.3","upperLimit":"43.6"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Fold Ratio (GMFR) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo","description":"GMFRs relative to the baseline titer were determined at each post-baseline time point. All GMFRs were based on log10-transformed data.","populationDescription":"Immunogenicity Evaluable Population (IEP): all study subjects who are consented, randomized, received the assigned treatments (both vaccinations), and had blood drawn for immunogenicity testing at baseline (Day 0) and both of the following time points: Day 21 and Day 35.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"ratio","timeFrame":"Day 14, Day 21, Day 28, Day 35, Day 90, Day 194","groups":[{"id":"OG000","title":"Group 1: 37.5 µg LT Patch","description":"heat-labile enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System"},{"id":"OG001","title":"Group 2: 0 µg LT Patch (Placebo)","description":"Placebo: Travelers' Diarrhea Vaccine System"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"34"}]}],"classes":[{"title":"GMFR LT IgG - Day 14","categories":[{"measurements":[{"groupId":"OG000","value":"10.4","lowerLimit":"7.4","upperLimit":"14.5"},{"groupId":"OG001","value":"1.2","lowerLimit":"0.7","upperLimit":"2.0"}]}]},{"title":"GMFR LT IgG - Day 21","categories":[{"measurements":[{"groupId":"OG000","value":"21.1","lowerLimit":"15.2","upperLimit":"29.2"},{"groupId":"OG001","value":"1.2","lowerLimit":"0.7","upperLimit":"1.9"}]}]},{"title":"GMFR LT IgG - Day 28","categories":[{"measurements":[{"groupId":"OG000","value":"31.0","lowerLimit":"23.5","upperLimit":"41.0"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.6","upperLimit":"1.4"}]}]},{"title":"GMFR LT IgG - Day 35","categories":[{"measurements":[{"groupId":"OG000","value":"34.7","lowerLimit":"26.6","upperLimit":"45.4"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.6","upperLimit":"1.4"}]}]},{"title":"GMFR LT IgG - Day 90","categories":[{"measurements":[{"groupId":"OG000","value":"16.0","lowerLimit":"12.4","upperLimit":"20.8"},{"groupId":"OG001","value":"0.4","lowerLimit":"0.3","upperLimit":"0.6"}]}]},{"title":"GMFR LT IgG - Day 194","categories":[{"measurements":[{"groupId":"OG000","value":"5.7","lowerLimit":"4.3","upperLimit":"7.5"},{"groupId":"OG001","value":"0.2","lowerLimit":"0.2","upperLimit":"0.4"}]}]},{"title":"GMFR LT IgA - Day 14","categories":[{"measurements":[{"groupId":"OG000","value":"8.0","lowerLimit":"5.8","upperLimit":"11.0"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.6","upperLimit":"1.6"}]}]},{"title":"GMFR LT IgA - Day 21","categories":[{"measurements":[{"groupId":"OG000","value":"12.5","lowerLimit":"9.3","upperLimit":"16.8"},{"groupId":"OG001","value":"1.0","lowerLimit":"0.7","upperLimit":"1.6"}]}]},{"title":"GMFR LT IgA - Day 28","categories":[{"measurements":[{"groupId":"OG000","value":"15.8","lowerLimit":"12.1","upperLimit":"20.7"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.6","upperLimit":"1.4"}]}]},{"title":"GMFR LT IgA - Day 35","categories":[{"measurements":[{"groupId":"OG000","value":"13.8","lowerLimit":"10.6","upperLimit":"17.9"},{"groupId":"OG001","value":"0.9","lowerLimit":"0.6","upperLimit":"1.3"}]}]},{"title":"GMFR LT IgA - Day 90","categories":[{"measurements":[{"groupId":"OG000","value":"7.1","lowerLimit":"5.5","upperLimit":"9.2"},{"groupId":"OG001","value":"0.6","lowerLimit":"0.4","upperLimit":"1.0"}]}]},{"title":"GMFR LT IgA - Day 194","categories":[{"measurements":[{"groupId":"OG000","value":"3.4","lowerLimit":"2.6","upperLimit":"4.6"},{"groupId":"OG001","value":"0.5","lowerLimit":"0.3","upperLimit":"0.8"}]}]}]},{"type":"PRIMARY","title":"Seroconversion (SCR) After First and Second Vaccination With LT Vaccine Patch and Comparison Against Placebo","description":"Definition of SCR:\n\n* Seroconversion IgG: ≥ 2-fold rise of LT IgG titer relative to baseline\n* Seroconversion IgA: ≥ 4-fold rise of LT IgA titer relative to baseline","populationDescription":"Immunogenicity Evaluable Population (IEP): all study subjects who are consented, randomized, received the assigned treatments (both vaccinations), and had blood drawn for immunogenicity testing at baseline (Day 0) and both of the following time points: Day 21 and Day 35.","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"Day 14, Day 21, Day 28, Day 35, Day 90, Day 194","groups":[{"id":"OG000","title":"Group 1: 37.5 µg LT Patch","description":"heat-labile enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System"},{"id":"OG001","title":"Group 2: 0 µg LT Patch (Placebo)","description":"Placebo: Travelers' Diarrhea Vaccine System"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"34"}]}],"classes":[{"title":"SCR LT IgG - Day 14","categories":[{"measurements":[{"groupId":"OG000","value":"77.6","lowerLimit":"66.6","upperLimit":"86.4"},{"groupId":"OG001","value":"8.8","lowerLimit":"1.9","upperLimit":"23.7"}]}]},{"title":"SCR LT IgG - Day 21","categories":[{"measurements":[{"groupId":"OG000","value":"89.5","lowerLimit":"80.3","upperLimit":"95.3"},{"groupId":"OG001","value":"8.8","lowerLimit":"1.9","upperLimit":"23.7"}]}]},{"title":"SCR LT IgG - Day 28","categories":[{"measurements":[{"groupId":"OG000","value":"97.4","lowerLimit":"90.8","upperLimit":"99.7"},{"groupId":"OG001","value":"2.9","lowerLimit":"0.1","upperLimit":"15.3"}]}]},{"title":"SCR LT IgG - Day 35","categories":[{"measurements":[{"groupId":"OG000","value":"97.4","lowerLimit":"90.8","upperLimit":"99.7"},{"groupId":"OG001","value":"5.9","lowerLimit":"0.7","upperLimit":"19.7"}]}]},{"title":"SCR LT IgG - Day 90","categories":[{"measurements":[{"groupId":"OG000","value":"98.7","lowerLimit":"92.8","upperLimit":"100"},{"groupId":"OG001","value":"9.1","lowerLimit":"1.9","upperLimit":"24.3"}]}]},{"title":"SCR LT IgG - Day 194","categories":[{"measurements":[{"groupId":"OG000","value":"83.3","lowerLimit":"72.7","upperLimit":"91.1"},{"groupId":"OG001","value":"0","lowerLimit":"0","upperLimit":"10.6"}]}]},{"title":"SCR LT IgA - Day 14","categories":[{"measurements":[{"groupId":"OG000","value":"57.9","lowerLimit":"46.0","upperLimit":"69.1"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"10.3"}]}]},{"title":"SCR LT IgA - Day 21","categories":[{"measurements":[{"groupId":"OG000","value":"71.1","lowerLimit":"59.5","upperLimit":"80.9"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"10.3"}]}]},{"title":"SCR LT IgA - Day 28","categories":[{"measurements":[{"groupId":"OG000","value":"82.9","lowerLimit":"72.5","upperLimit":"90.6"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"10.3"}]}]},{"title":"SCR LT IgA - Day 35","categories":[{"measurements":[{"groupId":"OG000","value":"81.6","lowerLimit":"71.0","upperLimit":"89.5"},{"groupId":"OG001","value":"2.9","lowerLimit":"0.1","upperLimit":"15.3"}]}]},{"title":"SCR LT IgA - Day 90","categories":[{"measurements":[{"groupId":"OG000","value":"68.0","lowerLimit":"56.2","upperLimit":"78.3"},{"groupId":"OG001","value":"3.0","lowerLimit":"0.1","upperLimit":"15.8"}]}]},{"title":"SCR LT IgA - Day 194","categories":[{"measurements":[{"groupId":"OG000","value":"50.0","lowerLimit":"38.0","upperLimit":"62.0"},{"groupId":"OG001","value":"0.0","lowerLimit":"0.0","upperLimit":"10.6"}]}]}]},{"type":"SECONDARY","title":"Evaluation of Safety of LT Vaccine Patch After First and Second Vaccination Compared to Placebo Patch","description":"LT subjects (Group 1) were followed for six months longer (until Day 380) than Placebo subjects (Group 2) (until Day 194)","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"13 months","groups":[{"id":"OG000","title":"Group 1: 37.5 µg LT Patch","description":"heat-labile enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System"},{"id":"OG001","title":"Group 2: 0 µg LT Patch (Placebo)","description":"Placebo: Travelers' Diarrhea Vaccine System"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"39"}]}],"classes":[{"title":"AEs : All AEs - vaccination 1","categories":[{"measurements":[{"groupId":"OG000","value":"75"},{"groupId":"OG001","value":"26"}]}]},{"title":"AEs : All AEs - vaccination 2","categories":[{"measurements":[{"groupId":"OG000","value":"76"},{"groupId":"OG001","value":"24"}]}]},{"title":"AEs : Local AEs - vaccination 1","categories":[{"measurements":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"19"}]}]},{"title":"AEs : Systemic AEs - vaccination 1","categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"18"}]}]},{"title":"AEs : Local AEs - vaccination 2","categories":[{"measurements":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"13"}]}]},{"title":"AEs : Systemic AEs - vaccination 2","categories":[{"measurements":[{"groupId":"OG000","value":"44"},{"groupId":"OG001","value":"18"}]}]},{"title":"Severe AEs : All AEs - vaccination 1","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"Severe AEs : All AEs - vaccination 2","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"Severe AEs : Local AEs - vaccination 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Severe AEs : Systemic AEs - vaccination 1","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"}]}]},{"title":"Severe AEs : Local AEs - vaccination 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Severe AEs : Systemic AEs - vaccination 2","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"}]}]},{"title":"AEs requiring Treatment : All AEs - vaccination 1","categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"6"}]}]},{"title":"AEs requiring Treatment : All AEs - vaccination 2","categories":[{"measurements":[{"groupId":"OG000","value":"33"},{"groupId":"OG001","value":"10"}]}]},{"title":"AEs requiring Treatment : Local AEs - vacc. 1","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"0"}]}]},{"title":"AEs requiring Treatment : Systemic AEs - vacc. 1","categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"6"}]}]},{"title":"AEs requiring Treatment : Local AEs - vacc. 2","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"}]}]},{"title":"AEs requiring Treatment : Systemic AEs - vacc. 2","categories":[{"measurements":[{"groupId":"OG000","value":"31"},{"groupId":"OG001","value":"10"}]}]},{"title":"related AEs : All AEs - vaccination 1","categories":[{"measurements":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"20"}]}]},{"title":"related AEs : All AEs - vaccination 2","categories":[{"measurements":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"13"}]}]},{"title":"related AEs : Local AEs - vaccination 1","categories":[{"measurements":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"19"}]}]},{"title":"related AEs : Systemic AEs - vaccination 1","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"5"}]}]},{"title":"related AEs : Local AEs - vaccination 2","categories":[{"measurements":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"13"}]}]},{"title":"related AEs : Systemic AEs - vaccination 2","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"3"}]}]},{"title":"Serious AEs : All AEs - vaccination 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Serious AEs : All AEs - vaccination 2","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]},{"title":"Serious AEs : Local AEs - vaccination 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Serious AEs : Systemic AEs - vaccination 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}]},{"title":"Serious AEs : Local AEs - vaccination 2","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Serious AEs : Systemic AEs - vaccination 2","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}]}]}]},{"type":"SECONDARY","title":"Evaluation of Residual LT in the Patch and on the Skin at the Patch Site Post-wear","populationDescription":"Summary statistics are only shown for the LT Group in a protocol pre-defined subset of subjects, results for the Placebo Group were below the Limit of detection in all cases","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"nanograms (ng)","timeFrame":"1 month","groups":[{"id":"OG000","title":"Group 1: 37.5 µg LT Patch","description":"heat-labile enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"22"}]}],"classes":[{"title":"Residual LT in the Patch (ng LT)","categories":[{"measurements":[{"groupId":"OG000","value":"15893","spread":"6980"}]}]},{"title":"Residual LT in the Swab (ng LT)","categories":[{"measurements":[{"groupId":"OG000","value":"7231","spread":"2939"}]}]},{"title":"Estimate of LT Delivered (ng LT)","categories":[{"measurements":[{"groupId":"OG000","value":"14376","spread":"7609"}]}]}]},{"type":"SECONDARY","title":"Evaluation of LT-specific Immune Responses One-year After Original Treatment Regimen in LT Patch Group","description":"GMT","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"GMT","timeFrame":"13 months","groups":[{"id":"OG000","title":"Group 1: 37.5 µg LT Patch","description":"heat-labile enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"}]}],"classes":[{"title":"GMT LT IgG - Day 380","categories":[{"measurements":[{"groupId":"OG000","value":"1653.7","lowerLimit":"1377.9","upperLimit":"1984.8"}]}]},{"title":"GMT LT IgA - Day 380","categories":[{"measurements":[{"groupId":"OG000","value":"122.3","lowerLimit":"98.3","upperLimit":"152.1"}]}]}]},{"type":"SECONDARY","title":"Evaluation of LT-specific Immune Responses One Year After Original Treatment Regimen in LT Patch Group","description":"GMFR","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"ratio","timeFrame":"13 months","groups":[{"id":"OG000","title":"Group 1: 37.5 µg LT Patch","description":"heat-labile enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"}]}],"classes":[{"title":"GMFR LT IgG - Day 380","categories":[{"measurements":[{"groupId":"OG000","value":"3.8","lowerLimit":"3.0","upperLimit":"4.9"}]}]},{"title":"GMFR LT IgA - Day 380","categories":[{"measurements":[{"groupId":"OG000","value":"2.4","lowerLimit":"1.8","upperLimit":"3.3"}]}]}]},{"type":"SECONDARY","title":"Evaluation of LT-specific Immune Responses One Year After Original Treatment Regimen in LT Patch Group","description":"SCR","reportingStatus":"POSTED","paramType":"NUMBER","dispersionType":"95% Confidence Interval","unitOfMeasure":"percentage of participants","timeFrame":"13 months","groups":[{"id":"OG000","title":"Group 1: 37.5 µg LT Patch","description":"heat-labile enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"76"}]}],"classes":[{"title":"SCR LT IgG - Day 380","categories":[{"measurements":[{"groupId":"OG000","value":"67.1","lowerLimit":"54.9","upperLimit":"77.9"}]}]},{"title":"SCR LT IgA - Day 380","categories":[{"measurements":[{"groupId":"OG000","value":"38.6","lowerLimit":"27.2","upperLimit":"51.0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","eventGroups":[{"id":"EG000","title":"Group 1: 37.5 µg LT Patch","description":"heat-labile enterotoxin of E. coli (LT): Travelers' Diarrhea Vaccine System","seriousNumAffected":1,"seriousNumAtRisk":81,"otherNumAffected":79,"otherNumAtRisk":81},{"id":"EG001","title":"Group 2: 0 µg LT Patch (Placebo)","description":"Placebo: Travelers' Diarrhea Vaccine System","seriousNumAffected":2,"seriousNumAtRisk":39,"otherNumAffected":32,"otherNumAtRisk":39}],"seriousEvents":[{"term":"Haemorrhoidal haemorrhage","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":81},{"groupId":"EG001","numAffected":1,"numAtRisk":39}]},{"term":"Non-cardiac chest pain","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":81},{"groupId":"EG001","numAffected":0,"numAtRisk":39}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":81},{"groupId":"EG001","numAffected":1,"numAtRisk":39}]}],"otherEvents":[{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":81},{"groupId":"EG001","numAffected":4,"numAtRisk":39}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":81},{"groupId":"EG001","numAffected":4,"numAtRisk":39}]},{"term":"Blood glucose increased","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":81},{"groupId":"EG001","numAffected":3,"numAtRisk":39}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":81},{"groupId":"EG001","numAffected":2,"numAtRisk":39}]},{"term":"Protein urine present","organSystem":"Investigations","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":81},{"groupId":"EG001","numAffected":3,"numAtRisk":39}]},{"term":"Application site discolouration","organSystem":"Injury, poisoning and procedural complications","stats":[{"groupId":"EG000","numAffected":62,"numAtRisk":81},{"groupId":"EG001","numAffected":5,"numAtRisk":39}]},{"term":"Application site erythema","organSystem":"Injury, poisoning and procedural complications","stats":[{"groupId":"EG000","numAffected":72,"numAtRisk":81},{"groupId":"EG001","numAffected":14,"numAtRisk":39}]},{"term":"Application site oedema","organSystem":"Injury, poisoning and procedural complications","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":81},{"groupId":"EG001","numAffected":0,"numAtRisk":39}]},{"term":"Application site pain","organSystem":"Injury, poisoning and procedural complications","stats":[{"groupId":"EG000","numAffected":22,"numAtRisk":81},{"groupId":"EG001","numAffected":3,"numAtRisk":39}]},{"term":"Application site pruritus","organSystem":"Injury, poisoning and procedural complications","stats":[{"groupId":"EG000","numAffected":72,"numAtRisk":81},{"groupId":"EG001","numAffected":8,"numAtRisk":39}]},{"term":"Application site rash","organSystem":"Injury, poisoning and procedural complications","stats":[{"groupId":"EG000","numAffected":77,"numAtRisk":81},{"groupId":"EG001","numAffected":5,"numAtRisk":39}]},{"term":"Malaise","organSystem":"General disorders","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":81},{"groupId":"EG001","numAffected":0,"numAtRisk":39}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"pointOfContact":{"title":"Head Clinical Development","organization":"Valneva Austria GmbH","email":"info@valneva.com","phone":"0043120620","phoneExt":"0"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"}},"hasResults":true}